Contrast safety in the cancer patient: preventing contrast-induced nephropathy

Abstract Cancer patients undergo frequent imaging examinations. Computed tomography (CT) examinations for tumor staging and assessment of treatment response generally require administration of intravascular contrast medium. Iodinated contrast agents for CT are associated with the risk of contrast-induced nephrotoxicity (CIN), particularly in patients with impaired renal function and diabetes. In many cancer patients the risk of complications from intravascular contrast medium administration is compounded by advanced age, dehydration and coadministration of nephrotoxic chemotherapeutic drugs. In this article I review the definition, clinical manifestations, possible mechanisms and risk factors for CIN, and provide recommendations for prevention of this potentially life-threatening complication.

• Publication year

  2008

• Venue

  Cancer Imaging

• Publication date

  2008-10-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1102/1470-7330.2008.9018PMID 18852085PMCID 2582505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ACTIVE Trial: Comparison of the Effects on Renal Function of Iomeprol-400 and Iodixanol-320 in Patients With Chronic Kidney Disease Undergoing Abdominal Computed Tomography

  2008cited by this paper
• Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity.

  2008cited by this paper
• Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels.

  2008cited by this paper
• The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.

  2008cited by this paper
• Current evidence on prevention and management of contrast-induced nephropathy

  2007cited by this paper
• Risk of iodinated contrast material--induced nephropathy with intravenous administration.

  2007cited by this paper
• Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

  2007cited by this paper
• Contrast-induced nephropathy: how it develops, how to prevent it.

  2006cited by this paper
• A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.

  2006cited by this paper
• Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis.

  2006cited by this paper
• The clinical and renal consequences of contrast-induced nephropathy.

  2006cited by this paper
• Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Computed Tomography: A Double-Blind Comparison of Iodixanol and Iopamidol

  2006cited by this paper
• Prevention of radiocontrast nephropathy.

  2005cited by this paper
• In which patients should serum creatinine be measured before iodinated contrast medium administration?

  2005cited by this paper
• The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients.

  2005cited by this paper
• Incidence of renal insufficiency in cancer patients

  2005cited by this paper
• Increased incidence of neoplasia in chronic renal failure (20-year experience)

  2004cited by this paper
• Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.

  2004cited by this paper
• Contrast-induced nephropathy.

  2004cited by this paper
• [Prevention of radiocontrast nephropathy].

  2003cited by this paper
• Guidelines for contrast media from the European Society of Urogenital Radiology.

  2003cited by this paper
• Epidemiology of contrast-induced nephropathy.

  2003cited by this paper
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

  2002cited by this paper
• European Society of Urogenital Radiology (ESUR)

  2001cited by this paper
• Contrast-media-induced nephrotoxicity: a consensus report

  1999cited by this paper
• Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).

  1999cited by this paper
• Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases.

  1998cited by this paper
• Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial

  1998cited by this paper
• Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.

  1997cited by this paper
• Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity.

  1997cited by this paper
• Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.

  1994cited by this paper
• Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media.

  1993cited by this paper
• Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial.

  1992cited by this paper
• Potential deleterious effect of furosemide in radiocontrast nephropathy.

  1992cited by this paper
• Failure to demonstrate contrast nephrotoxicity

  1991cited by this paper
• Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both

  1989cited by this paper
• Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study.

  1989cited by this paper
• Cholesterol embolization: a complication of angiography.

  1978cited by this paper
• Increased incidence of malignancy in chronic renal failure.

  1977cited by this paper
• Nonoliguric acute renal failure.

  1977cited by this paper
• Increased incidence of malignancy during chronic renal failure.

  1975cited by this paper

• Early Radiation Therapy Response Assessment using Multi-scale Photoacoustic Imaging

  2025cites this paper
• The Potential of Photoacoustic Imaging in Radiation Oncology

  2022cites this paper
• Artificial Intelligence in Radiation Therapy

  2021cites this paper
• Iodine-induced Nephropathy in Patients with Oncological Disorders Treated with Chemotherapy

  2020influential citation
• Photoacoustic imaging as a tool to probe the tumour microenvironment

  2019influential citation
• Prevention of contrast-associated acute kidney injury in cancer patients undergoing radiologic investigation using contrast media; a short-review to current knowledge

  2019cites this paper
• Risk of renal events following intravenous iodinated contrast material administration among inpatients admitted with cancer a retrospective hospital claims analysis

  2018cites this paper
• Big data in oncologic imaging

  2017cites this paper
• Metadata of the article that will be visualized in OnlineFirst

  2016cites this paper
• Use of Cystatin C and Serum Creatinine for the Diagnosis of Contrast-Induced Nephropathy in Patients Undergoing Contrast-Enhanced Computed Tomography at an Oncology Centre

  2015cites this paper
• Entanglement of sepsis, chronic kidney disease, and other comorbidities in patients who develop acute kidney injury.

  2015cites this paper
• Nefropatia induzida por contraste após tomografia computadorizada

  2015cites this paper
• Acute kidney injury in the cancer patient.

  2014cites this paper
• Contrast-Induced Nephropathy and Dehydration

  2013cites this paper
• Magnetic Resonance Imaging of Soft Tissue Infection with Iron Oxide Labeled Granulocytes in a Rat Model

  2012cites this paper
• [Renal toxicity of contrast agents in oncologic patients].

  2012cites this paper
• Effect of IV contrast medium on renal function in oncologic patients undergoing CT in ICU.

  2010cites this paper
• Phosphoglycerate Kinase 1 Promoting Tumor Progression and Metastasis in Gastric Cancer - Detected in a Tumor Mouse Model Using Positron Emission Tomography/Magnetic Resonance Imaging

  2006cites this paper